Home  |  Site Map  | Contact
Apr.22

QLT Inc. Completes Enrollment in its Natural History Study

   
apr. 4

QLT Announces Date of Special Distribution to Shareholders

   
Mar.21

QLT Provides Update on Special Distribution to Shareholders

   
Feb.25

QLT Announces 2015 Fourth Quarter and Year End Results

   
Feb.22

2016 Proxy Materials for Special Meeting

   
   
   
   
   
   
   
   
 

To view the “Clinical Proof-of-Concept Study of Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects with Impaired Dark Adaptation and/or Impaired Low Luminance Vision” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.

 
 
To view the “Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.
   
 
2014 Annual Report
For the Annual Report for the fiscal year ended December 31, 2014, click here.
   
   
   
   
   
   
 
Copyright 2000-2015 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
 
Employee Login
 
'ss